Pre-market movers: big gains on earnings beats and strategic deals

*together with Behind the Markets

Good day, 360!

Here are some of our top movers today. And don’t forget to register for Mission to Million — happening tomorrow at 1pm EST. Get on THIS LIST for all our upcoming events🔥. Be the best prepared trader on the Street!

FOCUS LIST🔎

EVER - Up over 25% in the pre-market after reporting better than requested earnings

GTBP - Up over 50% in pre after announcing request for withdrawal of form S-1 registration statement

RDHL - Up over 13% in pre after announcing it had licensed RHB-102 for commercialization worldwide excluding North America to Hyloris for up to $60 Million in potential milestone payments plus royalties  

HOTLIST🔥

EVER - Up over 25% in the pre-market after reporting better than requested earnings

EverQuote Inc. (EVER) operates an online marketplace for insurance shopping in the United States.

In the after-hours yesterday, the company reported Q4 and full year 2024 financial results.

Highlights include:

Fourth Quarter Revenue Growth of 165% Year-Over-Year to $147.5 million

Fourth Quarter Variable Marketing Dollars Increases Over 110% Year-Over-Year to $44.0 million

Fourth Quarter Net Income of $12.3 million and Adjusted EBITDA of $18.9 million

Full Year Revenue Grows 74% and Variable Marketing Dollars Increases 55%, Year-Over-Year

Full Year Net Income Increases to $32.2 million and Generates Operating Cash Flow of $66.6 million

Shares of EVER traded up over 25% in the pre-market in reaction to the news.

The first target for bulls is the pre-market high at $27. Beyond that, $28.09, $29, $31, $33, $35 and $36 come into play.

Below $27, targets to the downside are $26, $25.31, $24.11, $23, $22 and a gap fill at $20.15.

GTBP - Up over 50% in pre after announcing request for withdrawal of form S-1 registration statement

GT Biopharma Inc. (GTBP) is a clinical stage biopharmaceutical company that focuses on the development and commercialization of immuno-oncology products based on its proprietary Tri-specific Killer Engager (TriKE) fusion protein immune cell engager technology platform.

In the pre-market this morning, the company announced that it has filed a Request for Withdrawal with the U.S. Securities and Exchange Commission (SEC) with respect to the withdrawal of the company’s registration statement on Form S-1 (File No. 333-284032) that it filed with the SEC originally on December 23, 2024. 

The Registration Statement has not been declared effective by the SEC, and no securities have been sold in connection with the offering described in the Registration Statement.

Shares of GTBP traded up over 50% in the pre-market in reaction to the withdrawal of the potential share offering. 

The $2.80 area acted as support in the pre-market and will be an important level to watch. Above it, targets to the upside are $3.10, $3.20 and then the pre-market high at $3.40. Beyond that, $3.70 and $4.10 come into play.

Below $2.80, targets to the downside are $2.60, $2.40, $2.20 and then a gap fill at $2.03.

RDHL - Up over 13% in pre after announcing it had licensed RHB-102 for commercialization worldwide excluding North America to Hyloris for up to $60 Million in potential milestone payments plus royalties

RedHill Biopharma Ltd. (RDHL) is a specialty biopharmaceutical company that primarily focuses on gastrointestinal and infectious diseases.

In the pre-market this morning, the company announced that it had licensed RHB-102 for commercialization worldwide excluding North America to Hyloris for up to $60 Million in potential milestone payments plus royalties.

Highlights of the transaction include:

Hyloris will pay RedHill an upfront payment and up to $60 million in potential milestone payments, plus up to mid-20s percent royalties on revenues, in return for exclusive rights to develop and commercialize RHB-102 (Bekinda®) across all indications and territories outside the United States, Canada and Mexico

RedHill intends to continue development of RHB-102 for FDA approval in the U.S., if granted. Hyloris will be responsible for all development, regulatory and commercialization activities related to RHB-102 in its territories

The global antiemetics drugs market size was valued at approximately $7.5 billion in 2023 and is expected to grow at a CAGR of approximately 6% from 2024 to 2030

Positive results from the successful U.S. Phase 2 IBS-D study (RHB-102 12 mg) and Phase 3 GUARD gastroenteritis study (RHB-102 24 mg) were published in The American Journal of Gastroenterology and JAMA Network Open, respectively

Shares of RDHL traded up over 13% in the pre market in reaction to the news.

The $5.15 area acted as support and will be an important level to watch. Above it, targets to the upside are $5.40, $5.55, $6.15 and then the pre market high at $6.40. Beyond that, $6.80, $7 and $8 come into play.

Below $5.15, targets to the downside are $5.05, $4.90 and then a gap fill at $4.82 with $4.72 below that. 

MARKET NEWS 📰

Don't miss out on our MOBILE ALERTS!  Some of these alerts have rocketed 🚀past the MOON 🌝.  Text “RAGE” to 1-(888) 487-1534 📲.

*Disclosure: By texting “Alerts” to 1-(888) 487-1534, you agree to receive promotional messages sent via an autodialer. You also agree to the terms of service and privacy policy. This agreement isn’t a condition of any purchase. Message frequency varies. Message and data rates may apply. Reply STOP to opt out; HELP for more information.